NCT05562323
Characterization of Vaccine-induced Responses Against Monkeypox (MoVIHvax) An Observational Prospective Cohort Study
StatusCompleted
PhaseNot specified
Primary completion
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 8 versions: 7 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗
Notable Eligibility criteria expanded, about 3 words Show 4 more changesShow less
- Trial completed
- Final enrollment: 189 participants (planned 100)
- Study completion date changed from estimate of Aug 2026 to Aug 31, 2026
- Site details revised at 3 of 3 sites
- Minor Primary completion date changed from estimate of Jul 2026 to Jul 1, 2026v7
- Notable Primary completion date: Jan 2025 to Jul 2026
- Site details revised at 2 of 3 sites
- Notable Trial status: Active, Not Recruiting to Recruiting
- Primary completion date: Jun 23, 2023 to Jan 2025
- Study sites: 2 to 3
- Study completion date: Mar 20, 2026 to Aug 2026
- Minor Trial status: Recruiting to Active, Not Recruiting
- Primary completion date changed from estimate of Apr 23, 2023 to Jun 23, 2023
- Study completion date: Apr 23, 2023 to Mar 20, 2026
- Site details revised at 2 of 2 sites
- Minor Study description revisedv2
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Proportion of participants with detectable anti-orthopox antibodies
Timeframe: Between day 29 - 90
Quantification of anti-orthopox antibodies
Timeframe: Between day 29 - 90
Secondary (4)
Changes of the immunogenicity after the first vaccine dose
To compare immunogenicity between HIV negative and HIV positive individuals
Neutralization capacity of anti-orthopox antibodies
To compare neutralization capacity between HIV negative and HIV positive individuals
Arms and interventions
MKP vaccination for pre-exposure prophylaxis (HIV positive)
HIV positive individuals who receive MKP vaccination for pre-exposure prophylaxis
MKP vaccination for pre-exposure prophylaxis (seronegative individuals)
HIV seronegative individuals who receive MKP vaccination for pre-exposure prophylaxis
Sites
3 sites in 1 country